Jun Ke
About
In The Last Decade
Jun Ke
44 papers receiving 525 citations
Hit Papers
Peers
Comparison fields: 5 of 89
- Oncology 189
- Molecular Biology 109
- Pulmonary and Respiratory Medicine 99
- Cancer Research 95
- Radiology, Nuclear Medicine and Imaging 87
Countries citing papers authored by Jun Ke
This map shows the geographic impact of Jun Ke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Ke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Ke more than expected).
Fields of papers citing papers by Jun Ke
This network shows the impact of papers produced by Jun Ke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Ke. The network helps show where Jun Ke may publish in the future.
Co-authorship network of co-authors of Jun Ke
This figure shows the co-authorship network connecting the top 25 collaborators of Jun Ke. A scholar is included among the top collaborators of Jun Ke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Ke. Jun Ke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 5 | |
| 3 | 5 | |
| 4 | Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). breakdown → | 52 |
| 5 | 10 | |
| 6 | 3 | |
| 7 | 11 | |
| 8 | 1 | |
| 9 | 5 | |
| 10 | 10 | |
| 11 | 23 | |
| 12 | 8 | |
| 13 | 1 | |
| 14 | 16 | |
| 15 | 15 | |
| 16 | 2 | |
| 17 | 1 | |
| 18 | 47 | |
| 19 | 3 | |
| 20 | [The effects of calmodulin kinase II inhibitor on ventricular arrhythmias in rabbits with cardiac hypertrophy]. | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.